45 related articles for article (PubMed ID: 15279072)
21. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation.
Cauley JA; Norton L; Lippman ME; Eckert S; Krueger KA; Purdie DW; Farrerons J; Karasik A; Mellstrom D; Ng KW; Stepan JJ; Powles TJ; Morrow M; Costa A; Silfen SL; Walls EL; Schmitt H; Muchmore DB; Jordan VC; Ste-Marie LG
Breast Cancer Res Treat; 2001 Jan; 65(2):125-34. PubMed ID: 11261828
[TBL] [Abstract][Full Text] [Related]
22. The biological activities of 1alpha,25-dihydroxyvitamin D3 and its synthetic analog 1alpha,25-dihydroxy-16-ene-vitamin D3 in normal human osteoblastic cells and human osteosarcoma SaOS-2 cells are modulated by 17-beta estradiol and dependent on stage of differentiation.
Rao LG; Liu LJ; Rawlins MR; McBroom RJ; Murray TM; Reddy GS; Uskokovic MR; Rao DS; Sutherland MK
Biol Pharm Bull; 2001 Mar; 24(3):242-8. PubMed ID: 11256478
[TBL] [Abstract][Full Text] [Related]
23. Comparative effects of estrogen and antiestrogens on differentiation of osteoblasts in mouse bone marrow culture.
Qu Q; Härkönen PL; Väänänen HK
J Cell Biochem; 1999 Jun; 73(4):500-7. PubMed ID: 10733344
[TBL] [Abstract][Full Text] [Related]
24. An estrogen receptor basis for raloxifene action in bone.
Bryant HU; Glasebrook AL; Yang NN; Sato M
J Steroid Biochem Mol Biol; 1999; 69(1-6):37-44. PubMed ID: 10418979
[TBL] [Abstract][Full Text] [Related]
25. The addition of a raloxifene analog (LY117018) allows for reduced PTH(1-34) dosing during reversal of osteopenia in ovariectomized rats.
Hodsman AB; Drost D; Fraher LJ; Holdsworth D; Thornton M; Hock J; Bryant H; Watson PH
J Bone Miner Res; 1999 May; 14(5):675-9. PubMed ID: 10320515
[TBL] [Abstract][Full Text] [Related]
26. LY353381 x HCl: an improved benzothiophene analog with bone efficacy complementary to parathyroid hormone-(1-34).
Sato M; Zeng GQ; Rowley E; Turner CH
Endocrinology; 1998 Nov; 139(11):4642-51. PubMed ID: 9794476
[TBL] [Abstract][Full Text] [Related]
27. Estrogen via the estrogen receptor blocks cAMP-mediated parathyroid hormone (PTH)-stimulated osteoclast formation.
Kanatani M; Sugimoto T; Takahashi Y; Kaji H; Kitazawa R; Chihara K
J Bone Miner Res; 1998 May; 13(5):854-62. PubMed ID: 9610750
[TBL] [Abstract][Full Text] [Related]
28. Raloxifene.
Balfour JA; Goa KL
Drugs Aging; 1998 Apr; 12(4):335-41; discussion 342. PubMed ID: 9571395
[TBL] [Abstract][Full Text] [Related]
29. Parathyroid hormone exerts disparate effects on osteoblast differentiation depending on exposure time in rat osteoblastic cells.
Ishizuya T; Yokose S; Hori M; Noda T; Suda T; Yoshiki S; Yamaguchi A
J Clin Invest; 1997 Jun; 99(12):2961-70. PubMed ID: 9185520
[TBL] [Abstract][Full Text] [Related]
30. Two separate mechanisms for ligand-independent activation of the estrogen receptor.
El-Tanani MK; Green CD
Mol Endocrinol; 1997 Jun; 11(7):928-37. PubMed ID: 9178752
[TBL] [Abstract][Full Text] [Related]
31. Rapid protein kinase A--mediated activation of cyclic AMP-phosphodiesterase by parathyroid hormone in UMR-106 osteoblast-like cells.
Ahlström M; Lamberg-Allardt C
J Bone Miner Res; 1997 Feb; 12(2):172-8. PubMed ID: 9041048
[TBL] [Abstract][Full Text] [Related]
32. Effects of 1alpha,25-dihydroxy-16ene, 23yne-vitamin D3 on osteoblastic function in human osteosarcoma SaOS-2 cells: differentiation-stage dependence and modulation by 17-beta estradiol.
Rao LG; Sutherland MK; Reddy GS; Siu-Caldera ML; Uskokovic MR; Murray TM
Bone; 1996 Dec; 19(6):621-7. PubMed ID: 8968029
[TBL] [Abstract][Full Text] [Related]
33. Parathyroid hormone regulates osteoblast differentiation positively or negatively depending on the differentiation stages.
Isogai Y; Akatsu T; Ishizuya T; Yamaguchi A; Hori M; Takahashi N; Suda T
J Bone Miner Res; 1996 Oct; 11(10):1384-93. PubMed ID: 8889836
[TBL] [Abstract][Full Text] [Related]
34. Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: effects of raloxifene HCl, tamoxifen, estrogen, and alendronate.
Frolik CA; Bryant HU; Black EC; Magee DE; Chandrasekhar S
Bone; 1996 Jun; 18(6):621-7. PubMed ID: 8806005
[TBL] [Abstract][Full Text] [Related]
35. Cross talk of dual-signal transduction systems in the regulation of DNA synthesis by parathyroid hormone in osteoblastic osteosarcoma cells.
Kano J; Sugimoto T; Fukase M; Chihara K
J Bone Miner Res; 1993 Mar; 8(3):323-9. PubMed ID: 8384399
[TBL] [Abstract][Full Text] [Related]
36. 17 beta-estradiol and parathyroid hormone potentiate each other's stimulatory effects on alkaline phosphatase activity in SaOS-2 cells in a differentiation-dependent manner.
Rao LG; Wylie JN; Sutherland MS; Murray TM
Endocrinology; 1994 Feb; 134(2):614-20. PubMed ID: 8299560
[TBL] [Abstract][Full Text] [Related]
37. Parathyroid hormone induces sequential c-fos expression in bone cells in vivo: in situ localization of its receptor and c-fos messenger ribonucleic acids.
Lee K; Deeds JD; Chiba S; Un-No M; Bond AT; Segre GV
Endocrinology; 1994 Jan; 134(1):441-50. PubMed ID: 8275957
[TBL] [Abstract][Full Text] [Related]
38. Endogenous protein kinase-C activation in osteoblast-like cells modulates responsiveness to estrogen and estrogen receptor levels.
Migliaccio S; Wetsel WC; Fox WM; Washburn TF; Korach KS
Mol Endocrinol; 1993 Sep; 7(9):1133-43. PubMed ID: 8247015
[TBL] [Abstract][Full Text] [Related]
39. Elevation of alkaline phosphatase activity induced by parathyroid hormone in osteoblast-like cells from the spinal hyperostotic mouse TWY (twy/twy).
Terakado A; Tagawa M; Goto S; Yamazaki M; Moriya H; Fujimura S
Calcif Tissue Int; 1995 Feb; 56(2):135-9. PubMed ID: 7736322
[TBL] [Abstract][Full Text] [Related]
40. Parathyroid hormone and parathyroid hormone-related peptide activate the Na+/H+ exchanger NHE-1 isoform in osteoblastic cells (UMR-106) via a cAMP-dependent pathway.
Azarani A; Orlowski J; Goltzman D
J Biol Chem; 1995 Sep; 270(39):23166-72. PubMed ID: 7559463
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
